Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated, retaining the price target of $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy has given his Buy rating due to a combination of factors related to OS Therapies Incorporated’s promising advancements in their clinical trials. The company has recently completed enrollment for their Phase 1b trial of OST-504, an innovative immunotherapy targeting prostate cancer. This trial, which is expected to report data in the fourth quarter of 2025, could provide proof-of-concept if the results are positive, potentially paving the way for a later-stage trial.
Additionally, OS Therapies is making significant progress with their OST-HER2 program for osteosarcoma. The updated 2-year overall survival data from the Phase 2b trial has shown promising results, with the program moving towards a rolling BLA submission. This progress, coupled with the significant unmet need in these medical areas, enhances the likelihood of accelerated approval, supporting McCarthy’s optimistic outlook on the stock.